AQST Aquestive Therapeutics Inc

Price (delayed)

$0.74

Market cap

$31.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.75

Enterprise value

$135.24M

Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, ...

Highlights
Aquestive Therapeutics's revenue has increased by 8% YoY and by 2.3% from the previous quarter
AQST's net income is down by 28% year-on-year but it is up by 2.1% since the previous quarter
The EPS has declined by 11% year-on-year but it has grown by 5% since the previous quarter
AQST's equity has dropped by 80% year-on-year and by 13% since the previous quarter
The debt has grown by 27% YoY

Key stats

What are the main financial stats of AQST
Market
Shares outstanding
41.91M
Market cap
$31.02M
Enterprise value
$135.24M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.6
Earnings
Revenue
$51.98M
EBIT
-$48.92M
EBITDA
-$45.98M
Free cash flow
-$34.28M
Per share
EPS
-$1.75
Free cash flow per share
-$0.83
Book value per share
-$2.25
Revenue per share
$1.25
TBVPS
$1.36
Balance sheet
Total assets
$56.53M
Total liabilities
$149.67M
Debt
$118.96M
Equity
-$93.14M
Working capital
$18.4M
Liquidity
Debt to equity
-1.28
Current ratio
1.76
Quick ratio
1.43
Net debt/EBITDA
-2.27
Margins
EBITDA margin
-88.5%
Gross margin
68.4%
Net margin
-132.9%
Operating margin
-69%
Efficiency
Return on assets
-110.2%
Return on equity
N/A
Return on invested capital
-40.5%
Return on capital employed
-151.2%
Return on sales
-94.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AQST stock price

How has the Aquestive Therapeutics stock price performed over time
Intraday
-2.67%
1 week
4.8%
1 month
-26%
1 year
-82.87%
YTD
-80.98%
QTD
-71.65%

Financial performance

How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$51.98M
Gross profit
$35.53M
Operating income
-$35.89M
Net income
-$69.09M
Gross margin
68.4%
Net margin
-132.9%
AQST's net income is down by 28% year-on-year but it is up by 2.1% since the previous quarter
The net margin has contracted by 19% YoY but it has grown by 4.3% from the previous quarter
Aquestive Therapeutics's operating margin has increased by 11% YoY
Aquestive Therapeutics's gross margin has decreased by 9% YoY and by 3% QoQ

Growth

What is Aquestive Therapeutics's growth rate over time

Valuation

What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.6
The EPS has declined by 11% year-on-year but it has grown by 5% since the previous quarter
AQST's equity has dropped by 80% year-on-year and by 13% since the previous quarter
AQST's P/S is 80% below its last 4 quarters average of 3.0
Aquestive Therapeutics's revenue has increased by 8% YoY and by 2.3% from the previous quarter

Efficiency

How efficient is Aquestive Therapeutics business performance
AQST's ROA is down by 22% year-on-year
The return on sales has declined by 21% year-on-year
The company's return on invested capital rose by 4.3% QoQ

Dividends

What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AQST.

Financial health

How did Aquestive Therapeutics financials performed over time
The company's total assets is 62% lower than its total liabilities
Aquestive Therapeutics's total liabilities has increased by 32% YoY and by 3.8% QoQ
Aquestive Therapeutics's quick ratio has decreased by 24% YoY and by 22% QoQ
AQST's equity has dropped by 80% year-on-year and by 13% since the previous quarter
AQST's debt to equity is up by 29% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.